Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
Phase 1
Completed
- Conditions
- PainCancerColonic Disease
- Interventions
- Other: PlaceboDrug: GIC-1001 375 mg TIDDrug: GIC-1001 500 mg TIDDrug: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)Drug: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT02276768
- Locations
- 🇨🇦
Algorithme Pharma Inc., Montreal, Quebec, Canada
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT01926444
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸Precision Research Institute, San Diego, California, United States
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Colonic Diseases
- Interventions
- Drug: GIC-1001; 125 mg oral tabletsDrug: GIC-1001 matching placebo
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- gicare Pharma Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01738425
- Locations
- 🇨🇦
Algorithme Pharma Inc., Montreal, Quebec, Canada
News
No news found